Mass General Brigham launched a commercial spinout delivering a generative AI platform that interprets structured and unstructured clinical data to accelerate patient screening for clinical trials. The tool’s initial application is to improve accuracy and speed of matching candidates to protocols, addressing a persistent bottleneck in enrollment. The academic medical center framed the spinout as a route to scale internal analytics and offer enterprise-grade solutions to sponsors and CROs. Vendors and sites could adopt the platform to reduce manual chart review and increase screening throughput. Generative AI here refers to models that synthesize text and data outputs from mixed clinical inputs; companies will need to validate performance across EHR systems and demonstrate compliance with privacy laws when deployed at scale.